Abstract
Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival. This article contains areview of the literature of published studies on the topic of gastric cancer and peritoneal metastasis. The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7months under palliative second-line systemic treatment. The median survival time increased to 12months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies. Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
